104 related articles for article (PubMed ID: 12203105)
1. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients.
Ishibashi T; Yano Y; Oguma T
Cancer Chemother Pharmacol; 2002 Sep; 50(3):230-6. PubMed ID: 12203105
[TBL] [Abstract][Full Text] [Related]
2. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis.
Ishibashi T; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1273-81. PubMed ID: 15865078
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
4. Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion.
Ishibashi T; Fukumura K; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1283-9. PubMed ID: 15865079
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a formula for individual dosage of nedaplatin based on renal function.
Sato S; Fujiwara H; Oishi T; Shimada M; Machida S; Takei Y; Itamochi H; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2012 Mar; 69(3):599-603. PubMed ID: 21918903
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study for determination of the dosage formula for intra-arterial infusion chemotherapy with nedaplatin].
Ohbayashi Y; Miyake M; Iwasaki A; Ogawa T; Nagahata S; Toyama Y; Ohkawa M
Gan To Kagaku Ryoho; 2004 May; 31(5):713-6. PubMed ID: 15170978
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of concurrent chemoradiation with weekly nedaplatin in patients with squamous cell carcinoma of the uterine cervix.
Yoshinaga K; Niikura H; Ogawa Y; Nemoto K; Nagase S; Takano T; Ito K; Yaegashi N
Gynecol Oncol; 2007 Jan; 104(1):36-40. PubMed ID: 16889822
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.
Ishibashi T; Yano Y; Oguma T
Br J Clin Pharmacol; 2003 Aug; 56(2):205-13. PubMed ID: 12895194
[TBL] [Abstract][Full Text] [Related]
10. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
11. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
[TBL] [Abstract][Full Text] [Related]
13. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
14. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.
Lagrange JL; Médecin B; Etienne MC; Pivot X; Cassuto-Viguier E; Renée N; Thyss A; Ferrero JM; Otto J; François E; Milano G
Pharmacotherapy; 1997; 17(6):1246-53. PubMed ID: 9399607
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of the area under the blood concentration-time curve of targeting intra-arterial infusion chemotherapy with nedaplatin for primary oral cancer].
Ohbayashi Y; Miyake M; Iwasaki A; Ogawa T; Nagahata S; Toyama Y; Ohkawa M
Gan To Kagaku Ryoho; 2004 Jan; 31(1):41-4. PubMed ID: 14750319
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy for an esophageal cancer patient undergoing continuous ambulatory peritoneal dialysis for chronic renal failure and measurement of plasma concentration of the drug].
Okuyama M; Motoyama S; Maruyama K; Ohta H; Tsuchiya N; Oyake J; Ogawa J
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1029-32. PubMed ID: 16044967
[TBL] [Abstract][Full Text] [Related]
19. Serum cystatin C is a better marker of topotecan clearance than serum creatinine.
Hoppe A; Séronie-Vivien S; Thomas F; Delord JP; Malard L; Canal P; Chatelut E
Clin Cancer Res; 2005 Apr; 11(8):3038-44. PubMed ID: 15837759
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
Shen M; Schilder RJ; Obasaju C; Gallo JM
Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
